A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy

BACKGROUND: H.P. Acthar® Gel is currently the only Food and Drug Administration therapy approved for the treatment of nephrotic syndrome. Active drug ingredients include structurally related melanocortin peptides that bind to cell surface G-protein-coupled receptors known as melanocortin receptors,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hladunewich, Michelle A., Cattran, Daniel, Beck, Laurence H., Odutayo, Ayodele, Sethi, Sanjeev, Ayalon, Rivka, Leung, Nelson, Reich, Heather, Fervenza, Fernando C.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2014
Assuntos:
CLINICAL SCIENCE
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4106642/
https://ncbi.nlm.nih.gov/pubmed/24714414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfu069
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares